乳腺癌肝转移的介入治疗

Interventional Radiology Treatment of Liver Metastasis Caused by Breast Cancer

目的:评价乳腺癌肝转移介入治疗疗效,探讨其在乳腺癌肝转移综合治疗中的价值。方法:2000—2005年对68例乳腺癌肝转移患者共进行156次介入治疗,其中61例行超液化碘油栓塞。结果:应用世界卫生组织(WHO)实体瘤疗效评定标准评估治疗后疗效,68例中完全缓解(CR)0例(0%),部分缓解(PR)37例(54.41%),稳定(SD)26例(38.24%),进展(PD)5例(7.35%)。总客观有效率为54.41%。中位生存期为14个月,中位病灶稳定持续时间为9个月。6个月、l年、2年累积生存率分别为:92.60%、55.90%和17.00%。结论:乳腺癌肝转移的介入治疗疗效显著,毒副作用小,可以作为乳腺癌肝转移综合治疗中的主要治疗手段。

Objective： To analyze the efficiency of transhepatic arterial chemoembolization（TACE） for breast cancer patients with liver metastases （BCLM）, evaluate its value among the serial therapy of BCLM. Methods： The data of clinical characteristics, response to treatment and survival were retrospectively analyzed in 68 breast cancer patients from 2000 to 2005 with liver metastasis using. Results： According to the world health orgnization（WHO） criterion, among the 68 patients 0 patients had complete response,37 patients （54.41%） had partial response,26 patients （38.24%） had stable diseases,5 patients （7. 35%） had progress diseases. The overall response rate of whole group was 54.41%. The median disease free survival and median time to survival of this series was 9 months, 14 months, the cumulative 6, 12,24 months survival rates were 92.60% ,55.90%, 17.00%, respectively. Conclusion.. Transhepatic arterial chemoembolization is a safe and effective therapy for liver metastasis from breast cancer. It should be the first line choice of treatment for breast cancer patients with liver metastasis.